Better Health for All

Quince Therapeutics is developing eDSP/EryDex for Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease with an estimated median lifespan of 25-30 years.

This treatment aims to reduce chronic steroid toxicity while maintaining efficacy, and has shown a statistically significant reduction in neurological symptoms in a specific age subgroup (6-9 years old) in a per-protocol analysis. The company's entire business is devoted to this health improvement, delivering exceptional health benefits for a severe, unmet medical need. There is no evidence of revenue from harmful products. The product has a favorable long-term safety profile with no serious safety concerns observed in trials, and common adverse events were transient infusion-related pruritus and low serum iron levels. The clinical trials for eDSP are randomized, double-blind, and placebo-controlled, and the ATTeST trial involved 175 participants across 22 academic institutions in 12 countries and 5 continents, demonstrating excellent diversity and inclusion.

Fair Pay & Worker Respect

Quince Therapeutics' employee engagement, based on Glassdoor reviews from December 2025 to February 2026, shows an average rating of 3.2 out of 5 stars from 159 reviews.

59% of employees would recommend the company to a friend. The company's voluntary employee turnover is described as "extremely high" in a July 2025 Glassdoor article. There is no public record of labor-law or human-rights violations. For health insurance, a director was eligible for a monthly cash stipend of $1,800 to assist with health insurance premiums, but there is no company-wide coverage percentage for the general workforce.

Fair Trade & Ethical Sourcing

No evidence was found in the provided article regarding Quince Therapeutics, Inc.'s fair trade and ethical sourcing practices.

The article focuses on corporate governance documents and explicitly states that it contains no quantitative data or specific details related to ethical sourcing, supplier certifications, audit practices, labor incidents, supply chain traceability, remediation processes, ethical clauses in contracts, materials risk, or supplier diversity spend.

Honest & Fair Business

The company has a whistleblower policy and provides a confidential and anonymous hotline for complaints regarding accounting, internal accounting controls, or auditing matters.

This hotline is managed by the Audit Committee. However, no evidence is provided regarding independent investigation processes for these reports.

No War, No Weapons

The provided articles, including Quince Therapeutics, Inc.'s 2025 Annual Report, explicitly state that no data directly relevant to the 'No War, No Weapons' ethical value was found.

The report indicates 'N/A' for evidence across all relevant key metrics. The second article pertains to a different company (TriMas Corporation) and is not applicable to QNCX.US. Therefore, no KPIs can be scored based on the available information.

Planet-Friendly Business

In 2023, the company's total reported Scope 1, 2, and 3 emissions from laboratory operations, transportation, and waste management were 1,247 metric tons of CO2e.

This represents a 17.3% reduction in carbon emissions for the year. The overall waste recycling rate for 2023 was 73.4%, with specific recycling rates of 82.6% for biological waste, 68.9% for chemical waste, and 61.3% for general lab waste.

Respect for Cultures & Communities

No specific, concrete data points or facts related to the 'Respect for Cultures & Communities' ethical value were found in the provided articles for any of the KPIs.

The articles primarily discuss clinical trials and internal DEI ratings, explicitly stating that no data relevant to community respect metrics is present.

Safe & Smart Tech

Quince Therapeutics states its privacy policy is adopted in part to comply with the CCPA and represents compliance with Health Care Laws, including HIPAA, and Data Privacy Laws, including GDPR.

However, its privacy policy for California residents limits data requests to no more than two within any 12-month period and allows up to 90 days for a response, indicating basic control options with significant limitations and friction. The company collects various categories of personal data, including sensitive information, and retains it as long as required by law and for business needs, without specifying maximum retention periods, suggesting limited data minimization practices. Quince has a Vulnerability Responsible Disclosure Policy for security researchers and acknowledges them in a 'Hall of Fame' with certificates, but does not provide details on response times or monetary rewards, indicating a limited program. The company states it maintains administrative, technical, and physical safeguards to protect information but also notes it cannot ensure or warrant security and will not be liable for unauthorized processing.

Zero Waste & Sustainable Products

In 2023, the company achieved a recycling and repurposing rate of 73.4% for its total waste, which amounted to 42.6 metric tons.

This included an 82.6% recycling rate for 18.3 metric tons of biological waste, 68.9% for 12.7 metric tons of chemical waste, and 61.3% for 11.6 metric tons of general laboratory waste. The company uses 100% compostable poly bags and recycled plastic mailers for packaging. It also reports 100% compliance with international environmental research standards.